These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

940 related items for PubMed ID: 21786419

  • 1. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.
    Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.
    Exp Cell Res; 2005 Apr 01; 304(2):604-19. PubMed ID: 15748904
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
    Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A, Diermeier S.
    Cell Prolif; 2007 Aug 01; 40(4):488-507. PubMed ID: 17635517
    [Abstract] [Full Text] [Related]

  • 5. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K.
    Cancer Med; 2019 Mar 01; 8(3):1258-1268. PubMed ID: 30701699
    [Abstract] [Full Text] [Related]

  • 6. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 7. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.
    Breast Cancer Res; 2013 Jun 01; 15(5):R85. PubMed ID: 24044505
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X, Wong J, Sevinsky CJ, Kokabee L, Khan F, Sun Y, Conklin DS.
    Mol Cancer Ther; 2016 Sep 01; 15(9):2198-208. PubMed ID: 27256378
    [Abstract] [Full Text] [Related]

  • 10. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
    Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R.
    J Natl Cancer Inst; 2007 May 02; 99(9):694-705. PubMed ID: 17470737
    [Abstract] [Full Text] [Related]

  • 11. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N.
    Breast Cancer Res Treat; 2010 Sep 02; 123(2):387-96. PubMed ID: 19946741
    [Abstract] [Full Text] [Related]

  • 12. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K.
    Cancer Sci; 2007 Sep 02; 98(9):1498-503. PubMed ID: 17627612
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. RON confers lapatinib resistance in HER2-positive breast cancer cells.
    Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L.
    Cancer Lett; 2013 Oct 28; 340(1):43-50. PubMed ID: 23811285
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
    Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.
    Oncotarget; 2016 Dec 20; 7(51):84860-84871. PubMed ID: 27768588
    [Abstract] [Full Text] [Related]

  • 17. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
    Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.
    Breast Cancer Res; 2011 Dec 20; 13(6):R121. PubMed ID: 22123186
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
    Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX.
    Clin Cancer Res; 2014 Jan 15; 20(2):456-68. PubMed ID: 24097864
    [Abstract] [Full Text] [Related]

  • 20. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
    Nahta R, Yuan LX, Du Y, Esteva FJ.
    Mol Cancer Ther; 2007 Feb 15; 6(2):667-74. PubMed ID: 17308062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.